Methicillin-Resistant Staphylococcus aureus Infections

Medical Clinics of North America

Volumn 97, Issue 4, 2013, Pages 601-619

  Pottinger, Paul S ^a  

^a NONE   (United States)

Author keywords

Ceftaroline; Community acquired MRSA; Daptomycin; Linezolid; Methicillin resistant Staphylococcus aureus; MRSA; Vancomycin

Indexed keywords

AZTREONAM; CEFALEXIN; CEFTAROLINE; CEPHALOSPORIN DERIVATIVE; CHLORHEXIDINE GLUCONATE; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; DOXYCYCLINE; ERYTHROMYCIN; GENTAMICIN; LINEZOLID; LUNG SURFACTANT; MACROLIDE; METICILLIN; MINOCYCLINE; NAFCILLIN; OXACILLIN; PENICILLIN DERIVATIVE; PLACEBO; PSEUDOMONIC ACID; QUINOLONE DERIVATIVE; RIFAMPICIN; TETRACYCLINE DERIVATIVE; VANCOMYCIN; VIRULENCE FACTOR;

ABSCESS; BACTEREMIA; BACTERIAL COLONIZATION; BACTERIAL GENE; BACTERIUM ISOLATE; BACTERIURIA; BLOODSTREAM INFECTION; CARBUNCLE; CELLULITIS; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; DIFFERENTIAL DIAGNOSIS; DISEASE CONTROL; DRUG APPROVAL; ENDOCARDITIS; FOOD AND DRUG ADMINISTRATION; FURUNCULOSIS; HEALTH CARE PERSONNEL; HOSPITAL ACQUIRED PNEUMONIA; HOSPITALIZATION; HUMAN; INCISION; INFECTION CONTROL; INFECTION RISK; MECA GENE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NECROTIZING FASCIITIS; NONHUMAN; PNEUMONIA; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; RESEARCH; REVIEW; SKIN ABSCESS; SKIN AND SOFT TISSUE INFECTION; SKIN INFECTION; SOFT TISSUE INFECTION; STREPTOCOCCUS PYOGENES; TINEA PEDIS; TREATMENT RESPONSE; WOUND CARE;

EID: 84879705260     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2013.02.005     Document Type: Review

References (63)

1. Liu C., Bayer A., Cosgrove S.E., et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 2011, 52(3):285-292.
2. Fleming A. On the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. Influenzas. Br J Exp Pathol 1929, X:226.
3. Mailer JS, Mason B. Penicillin: medicine's wartime wonder drug and its production at Peoria, Illinois. Available at: http://www.lib.niu.edu/2001/iht810139.html.
4. Barrett F.F., McGehee R.F., Finland M. Methicillin-resistant Staphylococcus aureus at Boston city hospital. NEngl J Med 1968, 279:441-448.
5. Tsubakishita S., Kuwahara-Arai K., Sasaki T., et al. Origin and molecular evolution of the determinant of methicillin resistance in staphylococci. Antimicrobial Agents Chemother 2010, 54(10):4352-4359.
6. Tulinski P., Fluit A.C., Wagenaar J.A., et al. Methicillin-resistant coagulase-negative staphylococci on pig farms act as a reservoir of heterogeneous SCCmec elements. Appl Environ Microbiol 2011, 78(2):299-304.
7. Sun L., Klein E.Y., Laxminarayan R. Seasonality and temporal correlation between community antibiotic use and resistance in the United States. Clin Infect Dis 2012, 55(5):687-694.
8. Selva L., Viana D., Regev-Yochay G., et al. Killing niche competitors by remote-control bacteriophage induction. Proc Natl Acad Sci USA 2009, 106:1234-1238.
9. Regev-Yochay G., Dagan R., Raz M., et al. Association between carriage of Streptococcus pneumoniae and Staphylococcus aureus in children. JAMA 2004, 292:716-720.
10. van Gils E.J., Hak E., Veenhoven R.H., et al. Effect of seven-valent pneumococcal conjugate vaccine on Staphylococcus aureus colonisation in a randomised controlled trial. PLoS One 2011, 6:e20229.
11. Klevens R.M., Edwards J.R., Tenover F.C., et al. Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992-2003. Clin Infect Dis 2006, 42(3):389-391.
12. Graffunder E.M., Venezia R.A. Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials. JAntimicrob Chemother 2002, 49:999-1005.
13. Levine D.P., Cushing R.D., Jui J., et al. Community-acquired methicillin-resistant Staphylococcus aureus endocarditis in the Detroit Medical Center. Ann Intern Med 1982, 97(3):330-338.
14. Hunt C., Dionne M., Delorme M., et al. Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus-Minnesota and North Dakota, 1997-1999. MMWR Morb Mortal Wkly Rep 1999, 48(32):707-710.
15. Voyich J.M., Otto M., Mathema B., et al. Is Panton-Valentine leukocidin the major virulence determinant in community-associated methicillin-resistant Staphylococcus aureus disease?. JInfect Dis 2006, 194(12):1761-1770.
16. Shallcross L.J., Fragaszy E., Johnson A.M., et al. The role of the Panton-Valentine leucocidin toxin in staphylococcal disease: a systematic review and meta-analysis. Lancet Infect Dis 2013, 13(1):43-54.
17. Kreisel K.M., Stine O.C., Johnson J.K., et al. USA300 methicillin-resistant Staphylococcus aureus bacteremia and the risk of severe sepsis: is USA300 methicillin-resistant Staphylococcus aureus associated with more severe infections?. Diagn Microbiol Infect Dis 2011, 70(3):285-290.
18. Chambers H.F. Community-associated MRSA-resistance and virulence converge. NEngl J Med 2005, 352:1485-1487.
19. Cosgrove S.E., Sakoulas G., Perencevich E.N., et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003, 36(1):53-59.
20. Eells S.J., McKinnell J.A., Wang A.A., et al. Acomparison of clinical outcomes between healthcare-associated infections due to community-associated methicillin-resistant Staphylococcus aureus strains and healthcare-associated methicillin-resistant S. aureus strains. Epidemiol Infect 2012, 1-9.
21. Gorwitz R.J., Kruszon-Moran D., McAllister S.K., et al. Changes in the prevalence of nasal colonization with Staphylococcus aureus in the United States, 2001-2004. JInfect Dis 2008, 197(9):1226-1234.
22. Lowy F. Staphylococcus aureus infections. NEngl J Med 1998, 339:520-532.
23. Klein E., Smith D.L., Laxminarayan R. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005. Emerg Infect Dis 2007, 13(12):1840-1846.
24. Klevens M.R., Morrison M.A., Nadle J., et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007, 298(15):1763-1771.
25. Holzknecht B.J., Hardardottir H., Haraldsson G., et al. Changing epidemiology of methicillin-resistant Staphylococcus aureus in Iceland from 2000 to 2008: a challenge to current guidelines. JClin Microbiol 2010, 48(11):4221-4227.
26. Daum R.S. Clinical practice. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. NEngl J Med 2007, 357(4):380-390.
27. Jeng A., Beheshti M., Li J., et al. The role of beta-hemolytic streptococci in causing diffuse, nonculturable cellulitis: a prospective investigation. Medicine (Baltimore) 2010, 89(4):217-226.
28. Moran G.J., Krishnadasan A., Gorwitz R.J., et al. Methicillin-resistant S. aureus infections among patients in the emergency department. NEngl J Med 2006, 355(7):666-674.
29. Rajendran P.M., Young D., Maurer T., et al. Randomized, double-blind, placebo-controlled trial of cephalexin for treatment of uncomplicated skin abscesses in a population at risk for community-acquired methicillin-resistant Staphylococcus aureus infection. Antimicrobial Agents Chemother 2007, 51(11):4044-4048.
30. Lewis J.S., Jorgensen J.H. Inducible clindamycin resistance in Staphylococci: should clinicians microbiologists be concerned?. Clin Infect Dis 2005, 40:280-285.
31. Rybak M., Lomaestro B., Rotschafer J.C., et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009, 66:82-98.
32. Howden B.P., Ward P.B., Charles P.G., et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004, 38:521-528.
33. Soriano A., Marco F., Martínez J.A., et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008, 46(2):193-200.
34. Holmes N.E., Turnidge J.D., Munckhof W.J., et al. Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. JInfect Dis 2011, 204(3):340-347.
35. Khatib R., Jose J., Musta A., et al. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia. JAntimicrob Chemother 2011, 66(7):1594-1599.
36. Saravolatz L.D., Pawlak J., Johnson L.B. Invitro susceptibilities and molecular analysis of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus isolates. Clin Infect Dis 2012, 55(4):582-586.
37. Levin-Edens E., Bonilla N., Meschke J.S., et al. Survival of environmental and clinical strains of methicillin-resistant Staphylococcus aureus in marine and fresh waters. Water Res 2011, 45(17):5681-5686.
38. Lowe C.F., Romney M.G. Bedbugs as vectors for drug-resistant bacteria. Emerg Infect Dis 2011, 17(6):1132-1134. [letter], [serial on the Internet].
39. Buehlmann M., Frei R., Fenner L., et al. Highly effective regimen for decolonization of methicillin-resistant Staphylococcus aureus carriers. Infect Control Hosp Epidemiol 2008, 29(6):510-516.
40. Sande M.A., Courtney K.B. Nafcillin-gentamicin synergism in experimental staphylococcal endocarditis. JLab Clin Med 1976, 88:118-124.
41. Korzeniowski O., Sande M.A. Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: a prospective study. Ann Intern Med 1982, 97:496-503.
42. Lalani T., Boucher H.W., Cosgrove S.E., et al. Outcomes with daptomycin versus standard therapy for osteoarticular infections associated with Staphylococcus aureus bacteraemia. JAntimicrob Chemother 2008, 61(1):177-182.
43. Papadopoulos S., Ball A.M., Liewer S.E., et al. Rhabdomyolysis during therapy with daptomycin. Clin Infect Dis 2006, 42(12):e108-e110.
44. Kim P.W., Sorbello A.F., Wassel R.T., et al. Eosinophilic pneumonia in patients treated with daptomycin: review of the literature and US FDA adverse event reporting system reports. Drug Saf 2012, 35(6):447-457.
45. Fowler V.G., Boucher H.W., Corey G.R., et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. NEngl J Med 2006, 355(7):653-665.
46. Besece D, etal. Safety and clinical outcomes of daptomycin at doses ≥10 mg/kg. IDWeek National Meeting [poster abstract 115: 779]. San Diego, October 19, 2012.
47. Perez-Jorge E.V., Burdette S.D., Markert R.J., et al. Staphylococcus aureus bacteremia (SAB) with associated S. aureus bacteriuria (SABU) as a predictor of complications and mortality. JHosp Med 2010, 5(4):208-211.
48. Pulcini C., Matta M., Mondain V., et al. Concomitant Staphylococcus aureus bacteriuria is associated with complicated S. aureus bacteremia. JInfect 2009, 59:240-246.
49. Moise-Broder P.A., Forrest A., Birmingham M.C., et al. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharm 2004, 43(13):925-942.
50. Jeffres M.N., Isakow W., Doherty J.A., et al. Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest 2006, 130(4):947-955.
51. Wunderink R.G., Rello J., Cammarata S.K., et al. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003, 124:1789-1797.
52. Wunderink R.G., Niederman M.S., Kollef M.H., et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 2012, 54(5):621-629.
53. Teflaro (ceftaroline fosamil) [prescribing information] 2011, Forest Pharmaceuticals, St Louis (MO).
54. Rank D.R., Friedland H.D., Laudano J.B. Integrated safety summary of FOCUS 1 and FOCUS 2 trials: phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia. JAntimicrob Chemother 2011, 66(Suppl 3):iii53-iii59.
55. Friedland H.D., O'Neal T., Biek D., et al. CANVAS 1 and 2: analysis of clinical response at day 3 in two phase 3 trials of ceftaroline fosamil versus vancomycin plus aztreonam in treatment of acute bacterial skin and skin structure infections. Antimicrobial Agents Chemother 2012, 56(5):2231-2236.
56. Jenkins T.C., Price C.S., Sabel A.L., et al. Impact of routine infectious diseases service consultation on the evaluation, management, and outcomes of Staphylococcus aureus bacteremia. Clin Infect Dis 2008, 46(7):1000-1008.
57. Kallen A.J., Mu Y., Bulens S., et al. Health care-associated invasive MRSA infections, 2005-2008. JAMA 2010, 304(6):641-648.
58. Burton D.C., Edwards J.R., Horan T.C., et al. Methicillin-resistant Staphylococcus aureus central line-associated bloodstream infections in US intensive care units, 1997-2007. JAMA 2009, 301(7):727-736.
59. Available at: http://www.cdc.gov/winnablebattles/.
60. Bubeck Wardenburg J., Schneewind O. Vaccine protection against Staphylococcus aureus pneumonia. JExp Med 2008, 205(2):287-294.
61. Burnside K., Lembo A., Harrell M.I., et al. Vaccination with a UV-irradiated genetically attenuated mutant of Staphylococcus aureus provides protection against subsequent systemic infection. JInfect Dis 2012, 206(11):1734-1744.
62. Spellberg B., Daum R. Development of a vaccine against Staphylococcus aureus. Semin Immunopathol 2012, 34(2):335-348.
63. Fowler V, Allen K, Moreira E, etal. Efficacy and safety of an investigational Staphylococcus aureus vaccine in preventing bacteremia and deep sternal wound infections after cardiothoracic surgery. IDWeek National Meeting [oral abstract 180: LB-1]. San Diego, October 20, 2012.